FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303685384> ?p ?o ?g. }

• W4303685384 endingPage "7536" @default.
• W4303685384 startingPage "7524" @default.
• W4303685384 abstract "Treatment for acute myeloid leukemia (AML) typically involves intensive chemotherapy (IC); however, there is an unmet need for approximately 50% of AML patients who are deemed unfit or ineligible for IC. The purpose of this study was to evaluate, from a Canadian perspective, the economic impact of venetoclax in combination with azacitidine (Ven+Aza) for the treatment of patients with newly diagnosed AML who are 75 years or older or who have comorbidities that preclude using IC. A lifetime partitioned survival model was developed to assess the cost-effectiveness of Ven+Aza compared with Aza. Health states included event-free survival, progressive/relapsed disease, and death. Efficacy parameters were based on the VIALE-A trial. Analyses were conducted from Ministry of Health (MoH) and societal perspectives. Over a lifetime horizon, Ven+Aza was associated with a gain of 1.65 quality-adjusted life years (QALYs) compared with Aza. From an MoH perspective, Ven+Aza and Aza were associated with total costs of $204,305 and $82,333, respectively, resulting in an incremental cost–utility ratio of $73,841/QALY. Results were similar from a societal perspective. This economic evaluation demonstrates that, in comparison with Aza, Ven+Aza is a cost-effective strategy for the treatment of patients with newly diagnosed AML who are deemed unfit for IC." @default.
• W4303685384 created "2022-10-09" @default.
• W4303685384 creator A5002489867 @default.
• W4303685384 creator A5005974721 @default.
• W4303685384 creator A5015721906 @default.
• W4303685384 creator A5033270134 @default.
• W4303685384 creator A5060356377 @default.
• W4303685384 creator A5062507167 @default.
• W4303685384 creator A5072973420 @default.
• W4303685384 date "2022-10-08" @default.
• W4303685384 modified "2023-10-01" @default.
• W4303685384 title "Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis" @default.
• W4303685384 cites W14861118 @default.
• W4303685384 cites W1996383959 @default.
• W4303685384 cites W1998475390 @default.
• W4303685384 cites W2014405244 @default.
• W4303685384 cites W2050782849 @default.
• W4303685384 cites W2109065151 @default.
• W4303685384 cites W2160968219 @default.
• W4303685384 cites W2161245598 @default.
• W4303685384 cites W2173785701 @default.
• W4303685384 cites W2185856844 @default.
• W4303685384 cites W2405193268 @default.
• W4303685384 cites W2535056227 @default.
• W4303685384 cites W2553008980 @default.
• W4303685384 cites W2559537906 @default.
• W4303685384 cites W2622477796 @default.
• W4303685384 cites W2741998413 @default.
• W4303685384 cites W2764775166 @default.
• W4303685384 cites W2792543271 @default.
• W4303685384 cites W2800327377 @default.
• W4303685384 cites W2884570739 @default.
• W4303685384 cites W2895485327 @default.
• W4303685384 cites W2898284215 @default.
• W4303685384 cites W2974308092 @default.
• W4303685384 cites W2976049443 @default.
• W4303685384 cites W2997079384 @default.
• W4303685384 cites W3007005703 @default.
• W4303685384 cites W3013447738 @default.
• W4303685384 cites W3048827006 @default.
• W4303685384 cites W3131716652 @default.
• W4303685384 cites W3211747828 @default.
• W4303685384 cites W4205278684 @default.
• W4303685384 cites W4231346141 @default.
• W4303685384 cites W4282566433 @default.
• W4303685384 doi "https://doi.org/10.3390/curroncol29100592" @default.
• W4303685384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36290869" @default.
• W4303685384 hasPublicationYear "2022" @default.
• W4303685384 type Work @default.
• W4303685384 citedByCount "0" @default.
• W4303685384 crossrefType "journal-article" @default.
• W4303685384 hasAuthorship W4303685384A5002489867 @default.
• W4303685384 hasAuthorship W4303685384A5005974721 @default.
• W4303685384 hasAuthorship W4303685384A5015721906 @default.
• W4303685384 hasAuthorship W4303685384A5033270134 @default.
• W4303685384 hasAuthorship W4303685384A5060356377 @default.
• W4303685384 hasAuthorship W4303685384A5062507167 @default.
• W4303685384 hasAuthorship W4303685384A5072973420 @default.
• W4303685384 hasBestOaLocation W43036853841 @default.
• W4303685384 hasConcept C104317684 @default.
• W4303685384 hasConcept C126322002 @default.
• W4303685384 hasConcept C143998085 @default.
• W4303685384 hasConcept C150194340 @default.
• W4303685384 hasConcept C185592680 @default.
• W4303685384 hasConcept C190727270 @default.
• W4303685384 hasConcept C2776239401 @default.
• W4303685384 hasConcept C2777938653 @default.
• W4303685384 hasConcept C2778461978 @default.
• W4303685384 hasConcept C2778729363 @default.
• W4303685384 hasConcept C2779675984 @default.
• W4303685384 hasConcept C38652104 @default.
• W4303685384 hasConcept C41008148 @default.
• W4303685384 hasConcept C55493867 @default.
• W4303685384 hasConcept C71924100 @default.
• W4303685384 hasConcept C9583187 @default.
• W4303685384 hasConceptScore W4303685384C104317684 @default.
• W4303685384 hasConceptScore W4303685384C126322002 @default.
• W4303685384 hasConceptScore W4303685384C143998085 @default.
• W4303685384 hasConceptScore W4303685384C150194340 @default.
• W4303685384 hasConceptScore W4303685384C185592680 @default.
• W4303685384 hasConceptScore W4303685384C190727270 @default.
• W4303685384 hasConceptScore W4303685384C2776239401 @default.
• W4303685384 hasConceptScore W4303685384C2777938653 @default.
• W4303685384 hasConceptScore W4303685384C2778461978 @default.
• W4303685384 hasConceptScore W4303685384C2778729363 @default.
• W4303685384 hasConceptScore W4303685384C2779675984 @default.
• W4303685384 hasConceptScore W4303685384C38652104 @default.
• W4303685384 hasConceptScore W4303685384C41008148 @default.
• W4303685384 hasConceptScore W4303685384C55493867 @default.
• W4303685384 hasConceptScore W4303685384C71924100 @default.
• W4303685384 hasConceptScore W4303685384C9583187 @default.
• W4303685384 hasFunder F4320334371 @default.
• W4303685384 hasIssue "10" @default.
• W4303685384 hasLocation W43036853841 @default.
• W4303685384 hasLocation W43036853842 @default.
• W4303685384 hasLocation W43036853843 @default.
• W4303685384 hasOpenAccess W4303685384 @default.
• W4303685384 hasPrimaryLocation W43036853841 @default.

• next